Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab

doi:10.3748/wjg.v21.i17.5352

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 21, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (9505)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-1) series.

Item

Count

PDF

514

WORD

338

HTML

5532

Figures (1-2)

133

Tables (1-1)

126

Sum=6643

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

984

Download

1878

Sum=2862

May 7, 2015 (publication date) through Apr 24, 2024

Times Cited of This Article

Times Cited (4)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Randomized Clinical Trial

World J Gastroenterol. May 7, 2015; 21(17): 5352-5358
Published online May 7, 2015. doi: 10.3748/wjg.v21.i17.5352

Full Size Figure Download Figure

Figure 2 Progression-free survival (A) and overall survival (B) in the MAX trial patients with peritoneal disease: chemotherapy and bevacizumab vs chemotherapy alone. Chemo: Chemotherapy; Bev: Bevacizumab.

Citation: Roohullah A, Wong HL, Sjoquist KM, Gibbs P, Field K, Tran B, Shapiro J, Mckendrick J, Yip D, Nott L, Gebski V, Ng W, Chua W, Price T, Tebbutt N, Chantrill L. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab. World J Gastroenterol 2015; 21(17): 5352-5358
URL: https://www.wjgnet.com/1007-9327/full/v21/i17/5352.htm
DOI: https://dx.doi.org/10.3748/wjg.v21.i17.5352